Author
V. Oksenych
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2019-2023 · peak 4/yrCo-Author Collaboration Network
10 top collaborators · 45 mutual co-author links11 papers
Recent·Most cited
Broad-spectrum mono- and combinational drug therapies for global viral pandemic preparedness
A. Ianevski, R. Yao, R. M. Simonsen, V. Myhre, E. Ravlo, G. D. Kaynova, E. Zusinaite, J. M. White, Q. Pan, S. J. Polyak, V. Oksenych, M. P. Windisch, E. Lastauskiene, A. Vitkauskiene, A. Matukevicius, , D. E. Kainov
The paper develops scoring systems to predict novel broad-spectrum antivirals and combinations, aiming to improve preparedness for future viral outbreaks.
bioRxiv · Jan 15, 2022 · PreprintMicrobiology
Active components of commonly prescribed medicines affect influenza A virus-host cell interaction: a pilot study
A. Ianevski, R. Yao, E. Zusinaite, H. Lysvand, V. Oksenych, T. Tenson, M. Bjoras, D. E. Kainov
This study examines how active components of commonly prescribed medicines affect influenza A virus-host cell interactions both in silico and in vitro.
bioRxiv · Jul 11, 2021Pharmacology & Toxicology
Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection by targeting cooperatively host TMPRSS2 in vitro and in vivo
A. Ianevski, R. Yo, H. Lysvand, G. Grodeland, N. Legrand, V. Oksenych, E. Zusinaite, T. Tenson, M. Bjoras, D. E. Kainov
This study combines nafamostat and interferon-alpha to suppress SARS-CoV-2 infection by targeting TMPRSS2 in vitro and in vivo.
bioRxiv · Jun 16, 2021Microbiology
Interferon alpha-based combinations suppress SARS-CoV-2 infection in vitro and in vivo
A. Ianevski, R. Yao, E. Zusinaite, L. S. Lello, S. Wang, E. Jo, J. Yang, E. Ravlo, W. Wang, H. Lysvand, K. Loseth, V. Oksenych, T. Tenson, M. P. Windisch, M. Poranen, , D. E. Kainov
This study shows that IFNa-based combinations effectively inhibit SARS-CoV-2 infection in vitro and in vivo, with synergistic effects against other viruses.
bioRxiv · Jan 5, 2021 · PreprintMicrobiology
Identification of novel antiviral drug combinations in vitro and tracking their development
A. Ianevski, R. Yao, S. Biza, E. Zusinaite, A. Mannik, G. Kivi, A. Planken, K. Kurg, E.-M. Tombak, M. Ustav, N. Shtaida, E. Kulesskiy, E. Jo, J. Yang, H. Lysvand, , D. E. Kainov
This study identifies novel synergistic antiviral drug combinations effective against SARS-CoV-2, echovirus 1, HCV, and HIV-1 in vitro and provides an online resource for their developmental status.
bioRxiv · Sep 17, 2020 · PreprintMicrobiology
Potential antiviral options against SARS-CoV-2 infection
A. Ianevski, R. Yao, M. H. Fenstad, S. Biza, E. Zusinaite, H. Lysvand, K. Loeseth, V. M. Lamndsem, J. F. Malmring, V. Oksenych, S. E. Erlandsen, P. A. Aas, L. Hagen, C. H. Pettersen, J. E. Afset, , D. E. Kainov
The paper identifies potent convalescent sera and broad-spectrum antivirals effective against SARS-CoV-2 using a neutralization assay and cell culture screening.
bioRxiv · May 12, 2020Microbiology
Leaky severe combined immunodeficiency in mice lacking non-homologous end joining factors XLF and MRI
S. Castaneda-Zegarra, Q. Zhang, A. Alirezaylavasani, M. Fernandez-Berrocal, R. Yao, V. Oksenych
This study shows that XLF is functionally redundant with MRI and PAXX in lymphocyte development, and Mri interacts genetically with Dna-pkcs and Paxx in mice.
bioRxiv · Mar 4, 2020Immunology
Chemical, physical and biological triggers of Bcl-xL-mediated apoptosis
A. Ianevski, E. Kulesskiy, K. Krpina, G. Lou, Y. Aman, A. Bugai, K. Aasumets, Y. Akimov, D. Bulanova, K. Gildemann, A. F. Arutyunyan, O. Y. Susova, A. L. Zhuze, P. Ji, W. Wang, , D. E. Kainov
This study shows that Bcl-xL-specific inhibitors, when combined with DNA-damaging agents or physical insults, trigger apoptosis in various cell types and C. elegans by releasing Bad and Bax from Bcl-xL.
bioRxiv · Jan 13, 2020Cancer Biology
Critical Nodes of Virus-Host Interaction Revealed Through an Integrated Network Analysis
K. Bosl, A. Ianevski, T. T. Than, P. I. Andersen, S. Kuivanen, M. Teppor, E. Zusinaite, U. Dumpis, A. Vitkauskiene, R. J. Cox, H. Kallio-Kokko, A. Bergqvist, T. Tenson, V. Oksenych, M. Bjoras, , R. K. Kandasamy
This study identifies critical host-virus interaction nodes through network analysis and drug re-purposing, revealing key targets for antiviral therapies.
bioRxiv · Feb 13, 2019 · PreprintImmunology